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Delta
Notch ligandsa family member expressed broadly in the developing nervous system as neural
progenitor cells initiate differentiation. A proximal promoter sequence for Dll3 is conserved across multiple
species and is sufﬁcient to direct GFP expression in a Dll3-like pattern in the neural tube of transgenic mice.
This promoter contains multiple E-boxes, the consensus binding site for bHLH factors. Dll3 expression and
the activity of the Dll3-promoter in the dorsal neural tube depends on the basic helix–loop–helix (bHLH)
transcription factors Ascl1 (Mash1) and Neurog2 (Ngn2). Mutations in each E-box identiﬁed in the Dll3-
promoter allowed distinct enhancer or repressor properties to be assigned to each site individually or in
combination. In addition, each E-box has distinct characteristics relative to binding of bHLH factors Ascl1,
Neurog1, and Neurog2. Surprisingly, novel Ascl1 containing DNA binding complexes are identiﬁed that
interact with speciﬁc E-box sites within the Dll3-promoter in vitro. These complexes include Ascl1/Ascl1
homodimers and Ascl1/Neurog2 heterodimers, complexes that in some cases require additional undeﬁned
factors for efﬁcient DNA binding. Thus, a complex interplay of E-box binding proteins spatially and
temporally regulate Dll3 levels during neural tube development.
© 2009 Elsevier Inc. All rights reserved.IntroductionThe choice within neural progenitor populations to differentiate or
be maintained as a progenitor relies on the activity of bHLH trans-
cription factors in balance with the Notch signaling pathway. The
ability of proneural bHLH factors to induce differentiation is at least
partially accounted for by their transcriptional regulation of Notch
ligands, such as Dll1 and Dll3 (for reviews see Bertrand et al., 2002;
Kageyama and Ohtsuka, 1999; Louvi and Artavanis-Tsakonas, 2006).
Since Notch signaling results in down regulation of neural bHLH factor
activity, the regulation of Notch ligands as downstream targets of
neural bHLH factors is important in understanding the balance bet-
ween the progenitor state and initiation of differentiation.
Mammals have multiple Notch receptors (Notches 1–4), and mul-
tiple types ofNotch ligands,most notably those of theDelta and Serrate
families (Lendahl, 1998; Lindsell et al., 1996). Of the Delta family
including Dll1, Dll3, and Dll4 (Bettenhausen et al., 1995; Dunwoodie et
al., 1997; Shutter et al., 2000), Dll3 is the smallest and most divergent
as it shares only 36% overall amino acid homology with Dll1. Dll3 is
expressed along the entire dorsal–ventral axis of the neural tube in
cells that have recently exited the cell-cycle and have begun to diffe-
rentiate (Dunwoodie et al., 1997). Dll3 has a unique function in that
unlike Dll1, which functions as a classic Delta protein by stimulating
Notch signaling and inhibiting neural differentiation, Dll3 does notJ.E. Johnson).
l rights reserved.stimulate Notch signaling (Geffers et al., 2007; Ladi et al., 2005).
Indeed, in some instances it may actually function cell autonomously
to attenuate Notch signaling (Ladi et al., 2005). Here we examine the
regulation of Dll3 as a downstream target of the bHLH factors Ascl1
(previously Mash1) (Johnson et al., 1990) and Neurog2 (previously
Ngn2, Math4A) (Gradwohl et al., 1996) in the dorsal neural tube.
Proliferating neural progenitor cells reside in the ventricular zone
of the neural tube. As these cells initiate their differentiation program
they exit the cell cycle and move laterally out of this zone. Neural
bHLH factors such as Ascl1 and Neurog2 are expressed transiently in
neural progenitor cells in the ventricular zone in speciﬁc regions
and with distinct temporal characteristics throughout the developing
nervous system (Bertrand et al., 2002; Helms et al., 2005; Ma et al.,
1997; Sommer et al., 1996). They belong to a subclass of bHLH family
proteins that form heterodimers with E-protein bHLH factors (such as
Tcfe2a-E12/E47), bind DNA at E-box consensus sites, and activate
transcription (Gradwohl et al., 1996; Johnson et al., 1992; Massari and
Murre, 2000). Although recent advances have begun to identify target
genes regulated by Ascl1 and Neurog2, particularly in telencephalon
development (Castro et al., 2006), there is still much to be learned
about the molecular strategies used by these transcription factors to
control neural differentiation.
The importance of Ascl1 and Neurog2 in regulating Dll3 expression
is evident by the dramatic reduction in Dll3 levels in embryos mutant
for these bHLH factors (this report and Casarosa et al., 1999). Here we
show that Ascl1 and Neurog2 regulate Dll3 transcription in the mouse
dorsal neural tube through a complex series of E-box consensus
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containing Ascl1 homodimers or Ascl11/Neurog2 heterodimers that
likely contribute to this regulation. Thus, as neural progenitor cells
differentiate into neurons, Dll3 levels are regulated by the integrated
activity of the different bHLH factor complexes and speciﬁc E-boxes
within the Dll3 promoter. This integrated mode of regulation through
sequences proximal to the Dll3 gene is distinct from that reported for
the related Notch ligand Dll1, which appears to have discrete
enhancers responding either to Ascl1 or Neurog2 regulation (Castro
et al., 2006).
Materials and methods
DNA constructs
PCR was used to amplify the Dll3 proximal promoter from the
mouse genome. Using primers 5′-aaggatccTAATTTCCTGTCCGTTTG-3′
and 5′-aaccatggCTTTGGGGGACAGGATG-3′, a 640 bp promoter from
−640 to +3 was obtained and cloned into BamHI/NcoI sites of the
BgEGFP expression vector (Timmer et al., 2001) to generate Dll3wt-
GFP. This cloning replaces the basal promoter of BgEGFP with that of
the Dll3 gene. A PCR based site directed mutagenesis strategy was
used to generate each mutant construct. For E-box mutations the
CANNTG was mutated to CANNAT and the N-box from CACACGAG to
ATCACGTA. All constructs were sequenced to establish their integrity.
Transgenic mice
Transgenic mice were generated by standard procedures (Brinster
et al., 1985) using fertilized eggs from B6D2F1 (C57BL/6xDBA) or
B6SJLF1 (C57BL/6JxSJL) crosses. The Dll3-GFP fragments were isolated
from the vector with BamHI and XhoI following separation on a
standard 1% agarose gel. The DNA in the excised band was placed at
−20 °C for 10min atop a 45 μmmicroﬁltration column. After spinning
at top speed in a microfuge, the DNA in the ﬂow through was puriﬁed
using the QIAquick PCR Puriﬁcation Kit (Qiagen) according to the
manufacturer protocol. Each Dll3-GFP transgene was injected into
the pronucleus of fertilized mouse eggs at 1–3 ng/μl in 10 mM Tris
(pH 7.5), 0.1 mM EDTA. Transgenic embryos were identiﬁed by PCR
analysis using yolk sac DNA. Ascl1, Neurog2, and Neurog1 null mouse
strains were previously published (Fode et al., 1998; Guillemot et al.,
1993; Ma et al., 1998). Embryos were staged based on assumed
copulation at E0, halfway through the dark cycle.
mRNA in situ hybridization and GFP Visualization
For mRNA in situ hybridization, embryos were harvested at E11.5,
ﬁxed in PBS containing 4% formaldehyde for 2 h, rinsed in cold PBS,
incubated overnight in a 30% sucrose/PBS solution, embedded in OCT
and cryosectioned. In situ hybridizations were performed as pre-
viously described (Gowan et al., 2001) using probes speciﬁc for Dll3,
GFP, Ascl1, Neurog2, or Neurog1. Probes are available upon request.
Embryos were harvested at E9.5, E11.5, or E13.5 and directly
imaged for GFP ﬂuorescence. After whole mount images were taken,
embryos were ﬁxed in PBS containing 4% formaldehyde for 30 min at
room temperature, and processed for cyrosection as above. Whole
mount images were all taken at the same exposure times for com-
parative purposes using a Magna Fire imaging system attached to a
stereomicroscope with ﬂuorescence capabilities (Olympus). Cross
sections were imaged on a BioRad MRC 1024 confocal microscope
keeping all imaging parameters constant.
Chromatin Immunoprecipitation (ChIP)
ChIPwas performed similar to Castro et al. (2006) but usingmouse
E12.5 neural tube as tissue source. Brieﬂy, E12.5 neural tubes dissectedfromwild-type or Ascl1 null embryos were dissociated in cold PBS and
ﬁxed in 1% formaldehyde/PBS for 10 min at room temperature. Iso-
lated chromatin was sonicated to ∼0.5–1.2 kb. 15 μg of chromatin was
incubated with 2.5 μg antibody in 20 mM Hepes, 20 mM NaCl, 2 mM
EDTA, 0.1% Na-DOC, 1% Triton X-100, 1 mg/ml BSA, and protease
inhibitors overnight at 4 °C. Antibodies used were mouse anti-Ascl1
(BD Pharmingen anti-Mash1, 85103) and mouse anti-RNA Polymerase
II (Active Motif, 101307). Chromatin complexes were captured using
sheep anti-mouse IgG magnetic beads (Invitrogen Dynabeads M-280,
H54700). A detailed protocol for the ChIP assay is available upon re-
quest. Target DNAwas quantiﬁed by real time PCRwith Fast SYBRGreen
Master Mix (ABI) using an ABI 7500. % ChIP efﬁciency was calcu-
lated as (2(Threshold Cycle Input−Threshold Cycle ChIP))×1/dilution fac-
tor × 100. The following primers were used: Dll3 (fw)
TGCCCGAAGACTGAAGACTAATT, (rev) TGGGCTCAGGAAGGTGTGA;
Gapdh (fw) CACAGATGTCCAGCTGGTGACA, (rev) ATGATTCCAGG-
GATGGGTCTTGG; and from Castro et al. (2006) Dll1-M (fw)
GCGTGGCTGTCATTAAGG, (rev) GGTGCTGTCTGCATTACC; Dll1 ORF (fw)
GTCTCAGGACCTTCACAGTAG, (rev) GAGCAACCTTCTCCGTAGTAG.
Electromobility shift assays (EMSA)
In vitro translated proteins were synthesized with the TNT kit from
Promega, Inc. Translations were quantiﬁed using 35S Met according to
the manufacturers directions. Nuclear extracts were prepared from
mouse E10.5 neural tube using the CelLytic™ NuCLEAR™ Extraction
Kit from Sigma-Aldrich. TNT lysates or nuclear extracts were ﬁrst
added to binding buffer (20 mM Hepes pH 7.9, 10 mM MgCl2, 50 mM
KCl, 0.1 mM EDTA, 10% glycerol, 1 mM DTT, and 5 μg/ml Poly dI/dC)
and incubated at 30 °C for 15 min. (γ-32P)ATP end-labeled oligo probe
(50,000 cpm) was added and allowed to incubate for an additional
15 min. Complexes were separated on a 5.5% polyacrylamide matrix
gel run at 4 °C in 0.5% TBE under constant voltage at a rate of 10 V/cm
gel length. The amount of cold competitor probe was always in 100-
fold excess with respect to the labeled probe. Mutant competitors
used the same nucleotide changes found in their corresponding mu-
tant transgene constructs. Competitor oligonucleotides and antibodies
used for supershifts were added during the initial 15 minute incuba-
tion at 30 °C prior to the addition of the labeled probe. Rabbit poly-
clonal antibodies used in the super-shift assays were against Ascl1
(Chemicon, AB5696), Neurog2 (CeMines, AB/HLH2), GFP (Clontech,
8367-1), and E2a (Santa Cruz, SC-763X). For EMSA experiments
summarized in Fig. 5, probes were labeled and adjusted to the same
speciﬁc activity for comparison. EMSAs were quantiﬁed using a Storm
imaging system.
Oligonucleotides used in EMSA are indicated belowwith the E-box
underlined and the mutated nucleotides in lowercase:
E0-TGAGCCCAAATGGGAGGC;mE0-TGAGCCatAATGGGAGGC; E1-GAG-
GCCCAGCTGCGGCCC; mE1-GAGGCCCAGCatCGGCCC; E2-GCCCGGCAGA-
TGGCGACA; mE2-GCCCGGatGATGGCGACA; E3-TACATACAGCTGGGAGGC;
mE3-TACATAatGCTGGGAGGC; E4-AAGAAGGGGAAACACACATGCA-
TACA; mE4-AAGAAGGGGAAACACACaatCATACA; E5-GGAATGCACCTG-
TATTTC; mE5-GGAATGCACCatTATTTC; E6-ATCCAGCAGCTGCGACTC;
mE6-ATCCAGCAGCatCGACTC.
Transcription activation assay
Myc-tagged Ascl1, Neurog2, and Tcfe2a proteins were expressed
from pMiWIII derived vectors (Matsunaga et al., 2001; Suemori et al.,
1990). The tether peptide in the Ascl1 tethered proteins Ascl1tAscl1,
Ascl1tTcfe2a, and Ascl1tNeurog2 is AAAGTSAGGAAAGTSASAATGA.
These vectors are also myc-tagged and in pMiWIII expression
cassettes. The Fireﬂy luciferase reporters were constructed by cloning
a tandem repeat of six E2 or mE2 (sequences as above) E-box sites
upstream of the Ela1 basal promoter of EIp.Luc (Beres et al., 2006).
Fireﬂy luciferase reporters and phRL-TK (Renilla transfection control)
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embryonic kidney cells (ATCC CRL-1573) grown in 12 well tissue
culture plates. Cells were assayed 48 h post-transfection using a Dual
luciferase system kit (Promega). Fireﬂy Luciferase activity was
normalized to the Renilla activity for both the pE2Luc and pmE2Luc
reporters. Fold activation was calculated by comparing the activity of
the wild-type to mutant reporter (pE2Luc/pmE2Luc).
Results
A 640 bp proximal promoter in the Dll3 gene directs neural tube speciﬁc
expression
In order to discover regulatory sequences important in controlling
the expression of Dll3, we examined the sequence surrounding the
open reading frame for regions of conservation between the mouse
and human genomes. The Dll3 gene has a high degree of evolutionary
divergence that exposed a region of 640 bp strongly conserved
between themouse and human genomes (Evoprinter, Odenwald et al.,
2005). This 640 bp region is the only sequence outside of the Dll3
open reading frame that showed signiﬁcant conservationwithin 20 kb
surrounding the gene. The 640 bp sequence is located immediately
upstream of the start codon and extends beyond the predicted
transcriptional initiation site (Fig. 1A). Within the 640 bp are three
blocks of homology: Homology A is 78% identical over 250 bp,
Homology B is 77% identical over 13 bp, and Homology C is 70%
identical over 100 bp. To test the activity of this 640 bp promoter, we
assayed its ability to drive GFP expression in transgenic mouse
embryos. Six of six embryos expressing the (Dll3wt-GFP) transgene
had strong, consistent GFP signal at E11.5 in the neural tube, dorsal
root ganglia, hindbrain, ventral telencephalon, somites, and limbs (Fig.
1B, Dll3-WT). These domains accurately reﬂect the expression pattern
reported for Dll3 (Dunwoodie et al., 1997; Fig. 1), although GFP mRNA
and protein persist in more differentiated cells likely owing to
differences in stability relative to Dll3. These differences are visualized
by comparing Dll3 and GFP mRNA in the neural tube of E11.5 Dll3wt-
GFP embryos (Figs. 1C, D). Importantly, the 640 bp Dll3wt promoter
retains activity for many aspects of Dll3 expression including initiation
of expression in the ventricular zone and enriched expression at the
lateral edges of the ventricular zone (Figs. 1C′, D′), as well as
restriction to neural tissue.
This analysis was extended to multiple embryonic stages by
generating a stable transgenic line and assaying for GFP expression
(Supplemental Fig.1). Expression of GFP in the somites ﬁrst appears at
E9.5. At E13.5, expression was seen in the distal lateral muscle in the
limbs, telencephalon (striatum) and diencephalon (hypothalamus),
dorsal spinal cord, and retina. This spatial and temporal pattern of
expression for the GFP reporter also mimics expression of the
endogenous Dll3 gene (Dunwoodie et al., 1997). These observations
demonstrate that the 640 bp promoter contains sufﬁcient information
for transcriptional regulation of Dll3.
Efﬁcient activity of the 640 bp Dll3 promoter requires E-box sites
Contained within the conserved 640 bp sequence block are seven
E-boxes (Fig. 1A), the consensus binding site for the Class II neural
bHLH transcription factors (Murre et al., 1994). The functional signi-
ﬁcance of the E-box sequences was assessed by mutating all seven of
the E-box sites in the Dll3wt-GFP transgene and assaying GFP
expression at E11.5 in transgenic embryos (Fig. 1E, Dll3-mET). In the
absence of all E-boxes, therewas a dramatic reduction in the activity of
the promoter (3 transgenic embryos had detectable but low
expression). The low level GFP expression remaining was restricted
to the neural tube largely in the wild-type pattern (see Fig. 4, Dll3-
mET, inset). This result clearly establishes an important role for E-box
sequences in Dll3 regulation; however, it also indicates that the cell-type speciﬁc activity of the promoter is not solely dependent on these
E-box sequences.
Ascl1 and Neurog2 regulate Dll3 expression in the developing dorsal
neural tube
The identiﬁcation of a Dll3 promoter whose activity is dependent
on E-box sequences suggested that the E-box binding bHLH factors
present in the developing neural tube may directly regulate Dll3
levels through these sequences. To begin to address this possibility we
examined Dll3 expression in embryos mutant for the bHLH factors
Ascl1, Neurog2 and Neurog1. In wild-type mouse embryonic neural
tube at E11.5, Dll3 is expressed strongly at the lateral edge of the
ventricular zone (VZ) and in scattered cells in the dorsal VZ along the
entire dorsal/ventral axis (Fig. 2A). mRNA in situ hybridization for
Dll3 in null mutants of Ascl1 (Guillemot et al., 1993), Neurog2 (Fode
et al., 1998), and Neurog1 (Ma et al., 1998) was assessed (Figs. 2C, E,
G). Dll3 was most dramatically affected in the Ascl1 mutant. In this
mutant, Dll3 was not detected speciﬁcally within and adjacent to the
normal expression domain of Ascl1 (Figs. 2B, C). A subset of the Dll3
expression pattern was also lost in the Neurog2 mutant. In this case,
the strong lateral expression seen in the dorsal neural tube is clearly
lost (compare Fig. 2E with A). This is consistent with Neurog2
expression in the dorsal neural tube being enriched in the lateral,
more differentiated cells (Fig. 2D; Helms et al., 2005). No perturbation
in Dll3 was detected in the Neurog1 mutant (Figs. 2F, G). Thus, the
activity of Ascl1 and Neurog2, but not Neurog1, is required for proper
expression of Dll3 speciﬁcally in the dorsal neural tube. Furthermore,
the sequential nature of Ascl1 and Neurog2 expression in the dorsal
neural tube (Figs. 2B, D; Helms et al., 2005), and the discrete pattern of
Dll3 perturbation in the two mutants, suggests Dll3 is regulated by
integrating activities of multiple bHLH transcription factors.
The requirement for Ascl1 in the activity of the 640 bp Dll3
promoter was also tested in transgenic mice. Dll3wt-GFP transgenic
mice were bred onto the Ascl1mutant background. In the presence of
normal levels of Ascl1, Dll3wt-GFP expresses GFP in scattered cells
within the dorsal VZ, with intense GFP in more differentiated cells at
the lateral edges of the neural tube (Figs. 2H, H′). In the absence of
Ascl1, the scattered GFP cells in the VZ are absent and there are fewer
differentiated cells at the lateral edges of the dorsal neural tube (Figs.
2I, I′). It is likely thatmuch of the remaining GFP containing cells at the
lateral edge are from dI1 and dI2 interneurons streaming ventrally
from their origin in more dorsal regions. These populations do not
require Ascl1, rather they require the other bHLH factors Atoh1 and
Neurog1 (Gowan et al., 2001). The lack of GFP signal in the dorsal VZ is
consistent with a role for Ascl1 in activation of expression through the
Dll3 promoter. Similar experiments were attempted with Neurog2
mutant mice but no Dll3wt-GFP+;Neurog2−/− embryos were
obtained from over 10 litters suggesting the transgene randomly
inserted into the genome near the Neurog2 locus.
Ascl1 binds the Dll3 promoter in vivo
The dramatic loss of Dll3 expression in the Ascl1 mutant neural
tubes and the presence of binding consensus sites for bHLH factors in
the Dll3 promoter suggested that Ascl1 functions directly through at
least some of these sites. We used Chromatin Immuno-Precipitation
(ChIP) analysis to determine whether Ascl1 is localized to the Dll3
promoter in vivo. Chromatin was immunoprecipitated from formal-
dehyde cross-linked E12.5 neural tubes with antibodies speciﬁc to
Ascl1. To determine if Ascl1 localized to the Dll3 promoter, qPCR
analysis was performed using primers to this region. DNA immuno-
precipitated with Ascl1 antibodies showed signiﬁcant enrichment for
the Dll3 promoter target similar to a regulatory region for Dll1 (Dll1-
M), an enhancer that was previously shown to be directly regulated by
Ascl1 (Castro et al. 2006). Negative controls including the Dll1 open
Fig. 1. A proximal Dll3 promoter conserved between mouse and human directs Dll3 like expression in transgenic mice. (A) Diagram illustrating sequence homology regions A, B, and
C in the 5′ proximal sequence of Dll3. Sequence from mouse for each homology region is shown with capital letters indicating conserved nucleotides between human and mouse
sequences. Location relative to the start codon (ATG in bold) inmouse and human is given. E0–E6 E-boxes and an N-box are highlighted in red. The predicted transcription start site is
indicated by the arrow in Homology C. Oligonucleotide probes used for EMSA experiments are underlined. (B)Whole mount GFP ﬂuorescence in a transgenic embryo expressing GFP
under the control of the Dll3 proximal regulatory sequence (Dll3-WT). Dashed line indicates location of sections shown in (C, D). (C, D) Cross sections of the neural tubewith ﬂanking
dorsal root ganglia (arrows) showing mRNA in situ hybridization for Dll3 and GFP. Subpanels C′,D′ are higher magniﬁcation images of the dorsal neural tube highlighting the
ventricular zone (VZ). (E)Whole mount GFP ﬂuorescence in a transgenic embryo expressing GFP from the Dll3 promoter that has beenmutated at all seven E-box sites (Dll3-mET, see
Fig. 4 for diagram).
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Fig. 3. Ascl1 occupies the regulatory regions of Dll1 and Dll3 in embryonic neural tube.
Chromatin from E12.5 neural tubes immunoprecipitated using Ascl1 antibodies (top)
is enriched for the Dll3 promoter (Dll3) and a previously identiﬁed enhancer in Dll1
(Dll1-M) (Castro et al., 2006). Control DNA regions including the open reading frame of
the Dll1 gene (Dll1 ORF) and Gapdh are not enriched. Chromatin immunoprecipitated
with Ascl1 antibodies from Ascl1mutant neural tubes was not enriched for any regions
tested. The ChIP efﬁciency with chromatin immunoprecipitated using antibodies to RNA
polymerase II (bottom panel) is comparable or higher from the Ascl1 null tissue than
from wild-type tissue, conﬁrming the competence of the Ascl1 null tissue in this assay.
⁎⁎p valueb0.001, ⁎p valueb0.05.
Fig. 2. Dll3 expression and Dll3 promoter activity in the dorsal neural tube requires Ascl1 and Neurog2. (A–G) mRNA in situ hybridization on transverse sections of E11.5 mouse
neural tube. Dll3 expression in wild-type (A), Ascl1−/− (C), Neurog2−/− (E), and Neurog1−/− (G) embryos showing the requirement for Ascl1 for much of the dorsal Dll3
expression (between arrowheads in C), and Neurog2 for Dll3 expression in dorsolateral domains (dashed line in E compared to A). For reference, mRNA expression domains for Ascl1
(B), Neurog2 (D), and Neurog1 (F) in wild-type embryos are shown. (H, I) GFP ﬂuorescence in Dll3-GFP transgenic embryos at E11.5 in the presence (H, H′) or absence (I, I′) of Ascl1.
Subpanels H′, I′ are higher magniﬁcation images of (H, I) to highlight the loss of GFP cells in the ventricular zone (VZ) of the Ascl1mutants. Arrows indicate the dorsal root ganglia and
the arrowheads indicate the normal dorsal domain of Ascl1 expression.
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enrichment was seen with chromatin isolated from Ascl1 null neural
tubes (Fig. 3, top panel). Chromatin from wild-type and Ascl1 mutant
neural tubes was immunoprecipitated similarly with antibodies to
RNA polymerase II, demonstrating the chromatin from the mutant
neural tubes was competent in this assay (Fig. 3, bottom panel). These
results demonstrate Ascl1 directly binds to the Dll3 promoter in vivo
in E12.5 neural tubes.
In a similar set of experiments we utilized ChIP assays to test
whether Neurog2 directly binds to theDll3 promoter in vivo. Although
the Dll3 promoter was enriched after ChIP with Neurog2 antibodies
relative to negative controls, the efﬁciency of the pull-downs from
embryonic neural tubewas low, and thus, these experiments were not
deﬁnitive (data not shown).
Individual E-box sites have distinct properties with respect to
Dll3-promoter activity
The results above demonstrate that at least Ascl1 is directly
regulating the expression of Dll3 through the 640 bp Dll3 promoter.
Furthermore, the activity of the promoter requires intact E-box sites.
To more precisely deﬁne the contribution of each E-box to the activity
of the Dll3 promoter, the requirement for each individual E-box was
assayed in transgenic mice. The results reveal a complex use of the
E-box sequences for both activation and suppression of transgene
expression. Mutation of four of the E-boxes, E1, E3, E5, and E6, had
minor, if any, detectable effects on promoter activity when mutated
individually (Supplementary Fig. S2). However, when mutated in
combination, such as in Dll3-m3,5,6, enhancer activity was markedly
decreased (Fig. 4, Dll3-mE3,5,6). These data suggest a model in which
multiple, redundant E-box sites are important for Dll3 expression. In
contrast, individual mutations of E0, E2, and E4 revealed their indi-
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sections detail the properties of each of these sites for Dll3 promoter
activity.
E-boxes E0 and E4 serve major activator function in the Dll3 promoter
Of the seven E-boxes present in the promoter, only E-boxes E0 and
E4 were required to maintain activity of the Dll3 promoter when
tested individually. With each single mutation, a profound loss of
expressionwas seen in all embryos assayed (Fig. 4, Dll3-mE0 and Dll3-
mE4). To test whether E0 and E4 are sufﬁcient within the context of
the Dll3 promoter to drive the wild-type Dll3 pattern, a reconstructive
approach was taken. Starting with the E-box null mutant (Dll3-mET),
E0 and/or E4 were mutated back to wild-type creating three new
constructs — Dll3-mET+E0 (E0 only), Dll3-mET+E4 (E4 only), and
Dll3-mET+E0,4 (E0 and E4 only) (Fig. 4). When tested in transgenic
mice, E0 or E4 alone could rescue efﬁcient GFP expression throughout
the neural tube in all embryos expressing the transgene in a pattern
consistent with wild-type, albeit at a consistently reduced intensity
compared to the wild-type promoter (Fig. 4, compare Dll3-mET+E0
andDll3-mET+E4withDll3-WT). The inability of E0 or E4 individually
to restore the high level of GFP seen with the wild-type promoter
suggests their function may be additive. This was directly tested by
assaying Dll3-mET+E0,4. This construct directed efﬁcient expression
of GFP at levels exceeding the constructs with the individual E0 or E4
and approaching those seenwith the wild-type promoter (Fig. 4, Dll3-
mET+E0,4). However, relative to wild-type, this construct also
showed expanded expression within the brain and ectopic expression
in the mesenchyme, suggesting at least one of the other E-boxes has
repressor activity. Thus, in the wild-type promoter, the combined
activator activity of E0 and E4 must be attenuated by the presence of
the other E-boxes.
E-box E2 serves major repressor function in the Dll3 promoter
E-box E2, in contrast to E0 and E4, appears to play a major role as a
repressor. Mutation of E2 within the Dll3 promoter resulted in two
types of ectopic expression of the reporter gene thatwe term temporal
and tissue ectopic expression (Fig. 4, Dll3-mE2). Temporal ectopic
expression appears in the VZ, indicating that expression initiates in
cells more immature than in those seen with the wild-type promoter
(Fig. 4, Dll3-mE2, arrowhead). In contrast, tissue ectopic expression
appears in mesenchymal tissue surrounding the neural tube (Fig. 4,
Dll3-mE2, arrow). E2 thus appears to serve an important function in
Dll3 regulation by restricting its expression to neural progenitors of
the appropriate stage.
The presence of an N-box, the consensus binding site for Hairy/En
(S)/HES factors, in the promoter provided another candidate repressor
pathway to examine since these factors typically suppress neurogen-
esis (Kageyama et al., 1997; Sasai et al., 1992). Mutation of the N-box
resulted in temporal ectopic expression (Fig. 4), consistent with the
presence of Hes1 and Hes5 in the neural tube VZ at this time (Ohtsuka
et al., 1999). Notably, the tissue ectopic expression seen when E2 was
mutated was not detected with the N-box mutation demonstrating
that multiple mechanisms restrict activity of the Dll3 promoter.
The ectopic expression seen when the activator E-boxes E0 and E4
were the only E-boxes present (Fig. 3, Dll3-mET+E0,4) strongly
mimics the individual E2 mutant (Fig. 4, Dll3-mE2), implicating E2Fig. 4. E-box sites are required for activity of the 640 bp Dll3 promoter. Transient transgenic e
are shown in whole mount or as one half of a cross section through the neural tube. The bl
expression in the neural tube is indicated by +, and expression in limb or in ectopic locat
expression is early expression in the ventricular zone (arrowheads), and tissue ectopic expre
expressing embryos analyzed for each transgene is indicated (# Expressing). The images s
identical imaging parameters on the confocal for the cross sections. Each embryo is represent
gain to illustrate the low level GFP expression detected is restricted to Dll3 domains.function in attenuating E0/E4 activity. We tested this hypothesis by
constructing a transgene containing E2 plus E0 and E4 (Fig. 4, Dll3-
mE3,5,6). The presence of E2 dramatically repressed the ectopic
expression seen with the E0/E4 only mutant. The overwhelming loss
of expression in Dll3-mE3,5,6 suggests that in the context of the wild-
type promoter, the repressive activity of E2 must be modulated not
only by the activator E-boxes E0 and E4 but also by a combination of
the other E-boxes (E3, E5, and E6). In summary, of the seven E-boxes
tested, a dramatic affect on enhancer activity was detected for three;
E0 and E4 have enhancer activity, and E2 has repressor activity.
Dll3 promoter E-boxes are differentially bound by bHLH factors in vitro
Although ChIP analysis established that Ascl1 is bound to the Dll3
promoter in vivo, it is unable to spatially resolve interactions with
speciﬁc E-boxes or to provide insight into the speciﬁc complexes that
are involved. To determine the ability of Ascl1 and Neurog2 to interact
with speciﬁc E-boxes, we used EMSA with in vitro translated Ascl1,
Neurog2, and Tcfe2a-E12 (E12) proteins, as well as nuclear extracts
from E10.5 neural tube. A summary of the data obtained with in vitro
translated protein lysates is presented in Fig. 5A. There was surprising
variability in the binding of bHLH heterodimer complexes to each
E-box. An example of a typical experiment showing the classical
behavior of an E-box/ClassII bHLH interaction, using the E5 E-box
probe, is shown in Fig. 5B. E5 can be bound efﬁciently by E12 homo-
dimer (lane 2) and Ascl1/E12 heterodimer (lane 4), much less efﬁ-
ciently with Neurog2/E12 heterodimer (lane 7), and not at all by
Ascl1/Ascl1 homodimer (lane 3). Using this assay, we demonstrate
that each E-box has distinct properties with respect to the bHLH/E-
box complexes that can form in vitro.
Ascl1/E12 (Fig. 5A, black bars) and to a lesser extent Neurog2/E12
(Fig. 5A, dark gray bars) bound ﬁve of the seven E-boxes with varying
efﬁciencies. E-box E2 stood out as a strong Ascl1/E12 binding site. In
contrast, E0 and E4, the major enhancer E-boxes, were not efﬁciently
bound by Ascl1/E12 or Neurog2/E12. These ﬁndings were surprising
since Ascl1/E12 and Neurog2/E12 are known activators of transcrip-
tion (Gradwohl et al., 1996; Johnson et al., 1992).
In an attempt to identify an E-box binding bHLH transcription
activator that might act through the enhancer E-boxes E0 and E4, the
bHLH factor Nhlh1 (previously Nscl1, Hen1) was tested. We tested
Nhlh1 since it is expressed in the neural tube just lateral to the VZ as
cells become post-mitotic (Begley et al., 1992), an expression pattern
similar to Dll3wt-GFP. Nhlh1 bound efﬁciently as a heterodimer
with E12 speciﬁcally to E4, but not the other E-boxes (Fig. 5A). Thus,
Nhlh1 is one candidate that might upregulate Dll3 through this E-box
sequence.
Evidence for novel DNA binding complexes of Ascl1 including
homodimers and multi-factor complexes with Neurog2
The requirement of E-boxes E0, E2 and E4 for wild-type activity of
the Dll3 promoter was demonstrated in transgenic mice (Fig. 4). The
efﬁcient binding of Ascl1 and Neurog2 heterodimers to the E-box with
an apparent repressor activity (E2) but not to E-box E0 and E4 with
enhancer activity (Fig. 5A) presents an apparent contradiction since
Ascl1 and Neurog2 are transcriptional activators (Gradwohl et al.,
1996; Johnson et al., 1992). To gain further insight into the complexes
that can form on these E-box sequences, we used EMSAwith proteinsmbryos with awild-type or E-box mutant Dll3 promoter driving GFP expression at E11.5
ue circles represent each E-box, and the X indicates a mutation of the site. The relative
ions is indicated by Y (expression seen) or N (no expression seen). Temporal ectopic
ssion is expression detected aberrantly outside the neural tube (arrows). The number of
hown were obtained using identical exposure time for the whole mount embryos and
ative of those obtained for each transgene. The inset in Dll3-mETwas imaged at a higher
Fig. 5. EMSA using in vitro translated proteins reveal differences in bHLH complexes binding Dll3 promoter E-boxes. (A) A summary of multiple EMSA experiments with different in
vitro translated proteins showing band intensities for each E-box probe (E0-E6) normalized to the lowest measurable Ascl1/E12 heterodimer band (probe E3). No detectable gel
shifted band is shown as a box below the X-axis. Awhite box indicates that conditionwas not tested. (B) A representative EMSAwith E5 probe that generated the data summarized in
(A). In each case cold competitor oligonucleotides with wild-type or mutant E-box sequences demonstrate the requirement for the E-box. (C) EMSA demonstrating Ascl1/Ascl1
homodimers (lanes 2–6) and Ascl1/Neurog2 heterodimers (lanes 8–12) can bind E2 probe in an E-box dependent manner. Pretreating lysates with antibodies (ab) to Ascl1 and
Neurog2, but not control GFP disrupted formation of the Ascl1 containing complexes.
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Ascl1, Neurog2, and Tcfe2a-E12 (Fig. 6). This analysis revealed novel
Ascl1 and Neurog2 DNA binding complexes can form at least in vitro,
particularly to E2, the repressor E-box, and E4, an activator E-box.
Protein complexes with E-box E0
EMSA with nuclear extracts revealed a protein-DNA complex
formed on E0, but it did not require an intact E-box since competition
with a cold E-box mutant oligonucleotide efﬁciently competed for
binding (Fig. 6, lanes 1–3). Furthermore, the complexwas only slightly
blocked with pretreatment of the nuclear extracts with antibodies to
Ascl1 or Neurog2, and not at all with antibodies to Tcfe2a-E12 (Fig. 6A,
lanes 4–11). These results are consistent with the EMSA with in vitro
translated proteins where no bHLH was found to bind E0. Thus,
although E0 is required for Dll3 promoter activity, the proteins
involved in this activity were not identiﬁed (Fig. 5A).Protein complexes with E-box E2
E-box E2 has strong negative activity that keeps the Dll3 promoter
restricted to the neural tube and keeps it from turning on prematurely.
Using in vitro translated proteins, E2 can be bound efﬁciently by
E12/E12, Ascl1/E12, and Neurog2/E12 (Fig. 5A). Surprisingly, E2, but
none of the other E-boxes tested, was also efﬁciently bound by an
Ascl1/Ascl1 homodimer, a complex whose existence has not been
previously reported (Fig. 5C, lanes 2–5).
EMSA performed with E10.5 nuclear extracts also revealed E-box
dependent complexes binding E2, but the complex identiﬁed includes
both Ascl1 and Neurog2 (Fig. 6B, lanes 1–3). Pretreating the extracts
with antibodies speciﬁc to Ascl1 or to Neurog2 completely blocked the
formation of the same band demonstrating the existence of a novel
Ascl1/Neurog2 E-box binding complex (Fig. 6B, lanes 6 and 8). To
verify that we were detecting a speciﬁc interaction of the antisera to
Ascl1 and Neurog2 in the complex, we heat inactivated antisera prior
Fig. 6. EMSA using nuclear extracts reveal the formation of Ascl1/Neurog2 DNA binding complexes. Nuclear extracts (NE) from E10.5 mouse neural tube contain DNA binding
activities (lane 1) using oligonucleotides probes from E0 (A), E2 (B), and E4 (C). Except for E0, complex formation requires an intact E-box shown using cold competitor
oligonucleotides (lanes 2, 3). Extracts were preincubated with untreated or heat inactivated (Δ) antibodies (ab) speciﬁc to Ascl1, Neurog2, Tcfe2a-E12, or control GFP (lanes 4–13).
Arrows indicate the position of the complexes containing Ascl1 and Neurog2. The † indicates the lanes where complexes are lost with addition of speciﬁc antibodies to Ascl1 and
Neurog2 (B-lanes 6, 8; C-lanes 6, 8, 10). Asterisk in (C) indicates a new band revealed by depleting Ascl1 and Neurog2 from the extract. Models shown on the right depict proposed
complexes that bind each E-box.
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cases, there was no attenuation of the protein–DNA complex (Fig. 6B,
lanes 4–9). In addition, cross detection of Ascl1 by Neurog2 antisera
was not seen using in vitro transcribed and translated protein (Fig. 5C,
lanes 5–6). Antibodies to Tcfe2a-E12 had little if any effect on the
formation of the complexes (Fig. 6B, lanes 10–11). The ability of an
Ascl1/Neurog2 heterodimer to bind E2 E-box DNA was conﬁrmed
using in vitro translated proteins (Fig. 5C, lanes 8–12). Thus, E2 can be
bound by multiple Ascl1 containing complexes, including the classical
Ascl1/E12 heterodimer as well as an Ascl1/Ascl1 homodimer and
Ascl1/Neurog2 heterodimer.
Protein complexes with E-box E4
E-box E4 has strong enhancer activity in the Dll3 promoter (Fig. 4,
Dll3-mE4). Using in vitro translated proteins, only the heterodimer
Nhlh1/E12 bound E4 efﬁciently (Fig. 5A). EMSAwith nuclear extracts,
however, revealed a novel E-box binding transcription factor complex
that again includes Ascl1 and Neurog2, and also suggest it requires at
least one additional unidentiﬁed factor (Fig. 6C). The presence of Ascl1
and Neurog2 in the protein–E4 complex was demonstrated by the
complete disruption of the complex speciﬁcally with antibodies to
both Ascl1 and Neurog2, but not to Tcfe2a-E12 or to a control GFP (Fig.
6C, lanes 4–13). Surprisingly, blocking the Ascl1 and Neurog2
interaction with DNA by addition of speciﬁc antisera revealed a newprotein–DNA complex with faster mobility than the wild-type com-
plex (Fig. 6C, lanes 6,8,10 asterisk). This new complex also requires an
intact E-box (data not shown). The Ascl1/Neurog2 independent com-
plex revealed could normally be a component of a higher order
complex with these bHLH factors, or it could represent a binding
activity only revealed after Ascl1 and Neurog2 are removed from the
extract. However, consistent with the interpretation that an additional
factor is required in the Ascl1/Neurog2 complex with E4, in vitro
translated proteins alone cannot form an Ascl1/Neurog2 heterodimer
with E4 (Fig. 5A). Thus, a novel multimeric complex containing Ascl1,
Neurog2, and possibly another unidentiﬁed factor, or modiﬁcation of
the heterodimer, may play a role in Dll3 promoter activity.
Ascl1 homodimer and Ascl1/Neurog2 heterodimers function as
transcriptional activators
Two novel Ascl1 DNA binding complexes were identiﬁed via in
vitro EMSA analysis: Ascl1/Ascl1 homodimer and Ascl1/Neurog2
heterodimer. Both complexes can bind E2, the E-box that contains
repressor activity. To test a model whereby one or both of these two
novel heterodimeric complexes function to repress Dll3 expression, a
cell culture based luciferase assay was utilized. Ascl1, Neurog2, and
Tcfe2a-E12 were expressed in HEK293 cells with luciferase reporters
containing hexamers of either wild-type E2 or mutant mE2. The
Fig. 7. Ascl1/Ascl1 homodimers and Ascl1/Neurog2 heterodimers function as
transcriptional activators. The activity of Fireﬂy luciferase reporters with E-box E2 or
mutant E2 were assayed in HEK293 cells expressing various bHLH factors. Fireﬂy
luciferase activity for each reporter was normalized to control Renilla luciferase activity,
and then represented as the fold activation through the E2 elements versus the mutant
E2. pMiWIII is the empty expression vector. Tethered constructs are indicated by ‘t’. All
bHLH factors activated expression of the E2 reporter constructs but to varying extents.
Mean values are shown for n=6 transfections.
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wild-type E2 reporter relative to that from the mutant mE2 (Fig. 7).
Singly Ascl1, Neurog2, and E12 are all activators, with Neurog2 being
by far the strongest. Co-expressing Ascl1 with E12 dramatically
increases the transcriptional activation activity through the E2 se-
quence, consistent with the known function of the Ascl1/E12 hetero-
dimer as an activator complex. To bias the formation of speciﬁc Ascl1
complexes, expression constructs were designed to tether Ascl1
with a peptide to either Ascl1 itself to favor the homodimer, to
Neurog2 to favor the Ascl1/Neurog2 heterodimer, or to E12 to favor
the Ascl1/E12 heterodimer. The Ascl1 tethered homodimer (Ascl1-
tAscl1) and the Ascl1 tethered to E12 (Ascl1tE12) were both strong
activators in this assay. Ascl1 tethered to Neurog2 (Ascl1tNeurog2)
also activated transcription but to a much lesser extent. Taken to-
gether, in these reporter assays, all Ascl1 complexes appear to act as
activators, not repressors, but with varying efﬁciencies. Thus, the re-
pressor activity of E2 cannot easily be explained by binding of the
novel Ascl1 complexes, suggesting other factors bind E2 to repress
ectopic expression of Dll3.
Discussion
This study identiﬁes an evolutionarily conserved promoter res-
ponsible for Dll3 expression and demonstrates the regulation
through this promoter in the dorsal neural tube by the bHLH
transcription factors Ascl1 and Neurog2. The Dll3 promoter contains
multiple E-boxes, two of which are required and sufﬁcient for activity
of the promoter, and one that behaves as a repressor. Additional
E-boxes appear to function redundantly since these sites had to be
mutated in combination rather than individually to disrupt Dll3 pro-
moter activity.
Dll3 expression is a reﬂection of integrating speciﬁc binding
properties of multiple E-box binding complexes with distinct tem-
poral expression characteristics of each factor in these complexes.bHLH transcription factors represent one class of E-box binding pro-
teins whose importance were investigated in this study. The bHLH
factors Ascl1, Neurog2, and Nhlh1 accumulate in the dorsal neural
tube with distinct temporal characteristics. Ascl1 is present in neural
precursor cells prior to Neurog2 and Nhlh1 (Begley et al., 1992; Brown
et al., 1992; Helms et al., 2005) (Fig. 2). In the Ascl1 mutant, Dll3
expression is lost in the VZ in the dorsal domain where Ascl1 is
normally expressed. This is compared to the loss of Dll3 only in the
lateral, more differentiated cells in the Neurog2 mutant. Thus, integ-
ration of the activities of different bHLH complexes on the Dll3 pro-
moter results in its dynamic expression pattern and suggests that the
different bHLH factors act in a temporal cascade, possibly through
similar E-box sites.
One unanswered question in this study is how E-box E2 functions
to repress ectopic activity of the Dll3 promoter. E-box sites with
repressor function have been described previously (Genetta et al.,
1994; Weintraub et al., 1994). For example, the μE5 E-box within the
IgH enhancer acts as a repressor directed at MyoD in muscle pre-
sumably to maintain speciﬁcity of expression in B-cells. This activity
requires sequences within and adjacent to the E-box (Weintraub et al.,
1994). In addition, the zinc ﬁnger factor Zeb1 is an E-box binding
repressor that must be displaced for activation through the E-box
(Genetta et al., 1994). In the Dll3 promoter, E2 could be acting in a
similar way to repress activity of the promoter, a repression that can
be overcome by speciﬁc activator bHLH complexes.
The identiﬁcation of a single evolutionary conserved sequence that
contains multiple E-box sites suggests a strategy for regulation of Dll3
expression distinct from that shown for the related factor Dll1. In the
case of Dll1, two distinct and separable enhancers were identiﬁed
(Castro et al., 2006). Each enhancer contains E-box sequences, but
each enhancer is bound speciﬁcally by Ascl1 or Neurog2. When tested
in transgenic mice, one enhancer directs expression of a reporter in
the Ascl1 pattern while the other directs expression in a Neurog2
pattern. In contrast, the Dll3 promoter with its multiple E-box sites
directs expression of a reporter reﬂecting an additive pattern from
multiple bHLH factors.
Ascl1 is a component of several novel complexes that can bind the
Dll3 promoter
We show that Ascl1 is present in at least four different DNA binding
complexes that are capable of interacting with key regulatory E-boxes
present in the Dll3 promoter. In addition to the classical Ascl1/E12
heterodimer, we show binding activities for an Ascl1/Ascl1 homo-
dimer, an Ascl1/Neurog2 heterodimer, and a complex containing
some unknown factor or modiﬁcation in combination with Ascl1/
Neurog2 heterodimers. It is important to note that the existence of
these different DNA binding complexes can be demonstrated in vitro,
but their existence in vivo, and speciﬁcs of their in vivo contribution to
Dll3 expression has not been shown.
The primary active form of a class II bHLH factor such as Ascl1 is
thought to be as a heterodimer with an E-protein, such as Tcfe2a-E12
(see reviewMassari andMurre, 2000). Here we provide evidence that
an Ascl1/Ascl1 homodimer can exist as well. The homodimer binds
DNA with a similar apparent afﬁnity as the Ascl1/E12 heterodimer
but appears more selective in its sequence requirements in that of
the seven E-boxes tested, only E2 is a substrate for homodimer bind-
ing. The Ascl1 homodimer, however, is not the complex repressing
through E2 as we detected no obvious difference in the ability of the
homodimer and heterodimer to activate transcription.
Other novel DNA binding complexes were identiﬁed that contain
Ascl1/Neurog2 heterodimers. Although a protein–protein interaction
between Ascl1 and Neurog2 was previously reported, no DNA binding
activity could be attributed to the complex (Gradwohl et al., 1996).
Furthermore, there are no reports of a heterodimer of two class II
bHLH factors forming to bind DNA. Here we show that Ascl1/Neurog2
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and E4. Interestingly, only E2 functions as a substrate for in vitro
translated Ascl1/Neurog2 heterodimers. This suggests that there are
additional factors present in the nuclear extract from E10.5 neural
tube that stabilize the interactionwith E4, factors that are not required
for binding of the heterodimer to E2. The requirement for an addi-
tional factor for stable binding of bHLH factors has been shown for
homodimer formation of Myod and Tcfe2a-E12 (Anand et al., 1997). In
this case, the S5a subunit of the 26S proteasome complex is required
for stable homodimer binding to the muscle creatine kinase enhancer
E-box. Such a molecule may provide a similar function for the Ascl1/
Neurog2 heterodimer, allowing it to bind E4. Nevertheless, with or
without additional factors, the Ascl1/Neurog2 heterodimer clearly has
sequence speciﬁc DNA binding capabilities.
Ascl1 target DNA sequences
A major hurdle in fully understanding the function of any trans-
cription factor is the ability to identify its downstream targets. This is
true for neural bHLH factors as well, particularly since the core re-
cognition sequence of these factors is the degenerate E-box, CANNTG
(Bertrand et al., 2002; Massari and Murre, 2000). Recent advances are
revealing additional sequence recognition constraints as well as iden-
tifying compound sites that include transcription factor binding sites
neighboring the E-box (Castro et al., 2006; Powell et al., 2004; Singson
et al., 1994). In particular, Ascl1 has been shown to directly regulate
Dll1 synergistically with Brn factors (Pou domain containing factors)
in the telencephalon (Castro et al., 2006). Ascl1/E-protein hetero-
dimers plus Brn-family factors regulate Dll1 by binding DNA through a
compound site containing an E-box and the Brn consensus site,
thereby activating transcription. Using this extended consensus DNA
sequence, additional targets were identiﬁed that included E-box E3 of
Dll3 (Castro et al., 2006). However, mutation of this E-box site alone
did not dramatically disrupt enhancer activity as assayed in transgenic
mice (Fig. 4, Dll3-mE3). It is possible that the two-nucleotidemutation
tested here was not sufﬁcient to completely disrupt complex form-
ation at this site in vivo, particularly if the complex contains Ascl1 plus
a Brn factor with multiple protein–DNA contact surfaces as suggested
to occur in the telencephalon. Alternatively, there may be differences
in the co-factors used to activate Dll3 expression in the telencephalon
versus the neural tube.
Other direct targets of Ascl1 have been identiﬁed and include
transcription factors Dlx1/2 and Hes6 (Poitras et al., 2007), a secreted
factor PK2 (Zhang et al., 2007), and proprotein convertase Pace4
(Yoshida et al., 2001). Each of these targets contains a preferred Ascl1/
E-protein heterodimer E-box site: RCAGSTGK. Recently, a bioinfor-
matics approach was used to identify candidate co-factors for Ascl1
and Neurog2 during telencephalon development (Gohlke et al., 2008).
This analysis was restricted to targets with the preferred E-box site as
well. The existence of multiple Ascl1 transcription factor complexes
that have different sequence preferences, and possibly different afﬁ-
nities and transcription activities will complicate models of Ascl1 and
Neurog2 function. The combination of bHLH containing complexes at
any given time as a cell differentiates will have distinct but over-
lapping target gene speciﬁcity, and together with the genomic
organization of the E-boxes present, will determine the temporal
and spatial characteristics of downstream target expression.
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